GABPB1

GABPB1 is a transcription factor subunit that couples promoter-driven gene expression to telomerase activation, mitochondrial biogenesis, and redox/metabolic control (PMID:35460557, PMID:38081871, PMID:39496939). In cancers carrying mutant TERT promoters, GABPB1 is required for TERT expression and telomerase activation, and through this axis it drives metabolic reprogramming — sustaining pentose phosphate pathway flux (glucose-6-phosphate dehydrogenase activity, NADPH, and GSH) and glycolytic output (GLUT1, monocarboxylate transporters, and lactate dehydrogenase A) (PMID:35460557, PMID:36997627). GABPB1 also acts as a transcriptional regulator of mitochondrial inner-membrane genes, controlling mitochondrial function and proliferation (PMID:38081871), and transcriptionally activates the antioxidant gene PRDX5 to set cellular antioxidant capacity and resistance to ferroptosis (PMID:31700067). Its abundance and nuclear localization are post-translationally controlled: BAIAP2L2 binds GABPB1 and blocks its ubiquitin-dependent proteasomal degradation while promoting nuclear translocation, an axis that modulates ROS levels (PMID:39496939). GABPB1 is essential for development: its loss in mouse embryos causes preimplantation apoptotic arrest (PMID:37640449). Its functional output in cancer is context-dependent, behaving as a tumor-promoting factor in lung cancer yet restraining invasion and metastasis in thyroid cancer where its expression is silenced by promoter hypermethylation (PMID:38466508, PMID:35326537).

1. 2019 Medium

   Established a direct transcriptional target of GABPB1 in redox homeostasis, showing it activates the antioxidant peroxidase PRDX5 to govern ferroptosis sensitivity.

   Evidence knockdown/overexpression in HepG2 cells with PRDX5 mRNA/protein and ferroptosis viability readouts

   PMID:31700067

   Open questions at the time

   • lncRNA-mediated translational blockade of GABPB1 inferred but not reconstituted
   • direct binding of GABPB1 to the PRDX5 promoter not demonstrated
2. 2022 Medium

   Placed GABPB1 upstream of mutant TERT promoter activity and metabolic reprogramming, linking the transcription factor to telomerase, PPP/NADPH/GSH, and glycolytic lactate output.

   Evidence shRNA silencing in glioblastoma cells with MRS flux analysis, enzymatic assays, and in vivo tumor models

   PMID:35460557

   Open questions at the time

   • whether metabolic effects are fully mediated through TERT versus direct metabolic gene regulation not separated
   • single lab
3. 2022 Medium

   Revealed context-dependent and dual roles in cancer: required for mutant-TERT transcription yet acting as an epigenetically silenced tumor suppressor restraining thyroid cancer invasion.

   Evidence shRNA knockdown, invasion assays, zebrafish xenograft metastasis model, and DNA methylation inhibitor treatment in thyroid cancer cells

   PMID:35326537

   Open questions at the time

   • mechanism reconciling reduced TERT with increased invasion unresolved
   • not independently replicated
4. 2023 Medium

   Confirmed GABPB1 control of pentose phosphate pathway flux as a downstream consequence of mutant TERT promoter activation.

   Evidence stable and doxycycline-inducible shRNA lines with hyperpolarized 13C MRS in cells and in vivo tumors

   PMID:36997627

   Open questions at the time

   • direct transcriptional targets in the PPP not identified
   • single lab
5. 2023 Medium

   Identified GABPB1 as a key driver of mitochondrial biogenesis controlled upstream by a HOMER3-PAFAH1B3 complex regulating its protein levels.

   Evidence shRNA knockdown of HOMER3 in NSCLC cells with in vitro/in vivo functional assays and mechanistic follow-up

   PMID:38081871

   Open questions at the time

   • no direct binding assay for the HOMER3-GABPB1 relationship
   • specific mitochondrial inner-membrane target genes not enumerated
6. 2023 High

   Demonstrated GABPB1 is an essential developmental gene and an H3K9me3-repressed barrier to embryo reprogramming, whose mRNA supplementation rescues cloned embryo development.

   Evidence CRISPR/Cas9 knockout in mouse embryos, siRNA screen of H3K9me3-repressed genes, and mRNA supplementation rescue with apoptosis assays

   PMID:37640449

   Open questions at the time

   • downstream effector genes mediating the apoptotic arrest not defined
   • relationship to its transcriptional targets in development unmapped
7. 2024 Medium

   Defined post-translational control of GABPB1, showing BAIAP2L2 stabilizes it against ubiquitin-dependent degradation and drives nuclear translocation within an NFkB1-BAIAP2L2-GABPB1 axis regulating ROS and drug resistance.

   Evidence Co-IP, ubiquitination assays, subcellular fractionation, ROS measurements, and promoter-binding assays in hepatocellular carcinoma cells

   PMID:39496939

   Open questions at the time

   • E3 ligase mediating GABPB1 ubiquitination not identified
   • single Co-IP-based interaction without reciprocal structural validation
8. 2024 Low

   Reinforced a cancer-promoting role in lung cancer at the cellular level.

   Evidence shRNA knockdown with proliferation, colony formation, and apoptosis assays in A549 and H1299 NSCLC cells

   PMID:38466508

   Open questions at the time

   • no defined molecular pathway for GABPB1 action in this context
   • single cell-based approach, single lab

• The direct genome-wide transcriptional targets of GABPB1 and the structural basis of its assembly into the GABP complex remain uncharacterized in this corpus.
• no genome-wide binding map of GABPB1 in the timeline
• molecular partner within the GABP complex (the alpha subunit) not characterized here
• mechanistic basis for tumor-suppressor versus oncogenic switch unresolved